Prescribing of anti‐osteoporotic therapies following the use of proton pump inhibitors in general practice

McGowan, B; Bennett, Kathleen; Barry, Michael

doi:10.1002/pds.1972

Cited by 12 publications

(10 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BMD). Our findings are consistent with the only other study [1] that used osteoporosis medication as an indicator of bone health. The results of studies with other outcomes are inconsistent.…”

Section: Discussionsupporting

confidence: 92%

“…Acid-related upper gastrointestinal disorders are common in the developed world [1]. Consequently, proton pump inhibitors (PPIs) to treat these disorders are among the most widely prescribed medications worldwide [1,2].…”

Section: Introductionmentioning

confidence: 99%

“…Consequently, proton pump inhibitors (PPIs) to treat these disorders are among the most widely prescribed medications worldwide [1,2]. PPIs are indicated for several acid-related upper gastrointestinal disorders, including gastro-oesophageal disease (GERD), dyspepsia, peptic ulcer disease and as prophylaxis for non-steroidal anti-inflammatory drugs-associated upper gastrointestinal complications [3].…”

Section: Introductionmentioning

confidence: 99%

“…PPIs are indicated for several acid-related upper gastrointestinal disorders, including gastro-oesophageal disease (GERD), dyspepsia, peptic ulcer disease and as prophylaxis for non-steroidal anti-inflammatory drugs-associated upper gastrointestinal complications [3]. Due to their effectiveness and perceived short-and long-term safety, PPIs account for 95% of acid suppressing medication prescriptions [1]. In Australia, PPI prescribing tripled from 45 in 2001 to 130 defined daily dose (DDD)/1000 concession beneficiaries/day in 2005 [4].…”

Section: Introductionmentioning

confidence: 99%

“…In contrast, a study by Maggio et al [16] found that PPI use was significantly associated with decreased trabecular BMD, possibly an early marker of osteoporosis. One study found that PPI-users were more likely to subsequently be prescribed osteoporosis medication than non-users and that increased duration of therapy was associated with higher risks of osteoporosis medication prescription [1]. Three studies examining the effect of PPI use on calcium uptake used the dual isotope test (golden standard for intestinal calcium absorption) and these showed no evidence for decreased calcium absorption among PPI users [17][18][19].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study

Hoorn

Tett

Vries

et al. 2015

Bone

View full text Add to dashboard Cite

Please cite this article as: van der Hoorn Mariëlle M.C., Tett Susan E., de Vries Oscar J., Dobson Annette J., Peeters G.M.E.E. (Geeske), The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: a prospective cohort study, Bone (2015Bone ( ), doi: 10.1016Bone ( /j.bone.2015 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT 2 ABSTRACT Objectives:Proton pump inhibitors (PPIs) are among the most prescribed medications worldwide, however, there is growing concern regarding potential negative effects on bone health. The aim was to examine the effect of dose and type of PPI use on subsequent use of osteoporosis medication and fractures in older Australian women. Methods:Data were included from 4432 participants (born 1921-26) Conclusion:An appropriate benefit/risk assessment should be made when prescribing PPIs, especially for esomeprazole and rabeprazole, as osteoporosis and fracture risks were increased in this cohort of elderly females subsequent to PPI prescription. Highlights Proton pump inhibitor (PPI) use in elderly (>77 years) women was associated with increased risk of decreased bone health. Increased risk of subsequent osteoporosis medication was associated with the most commonly prescribed PPI, esomeprazole, and with rabeprazole and use of multiple different PPIs.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study

Hoorn

Tett

Vries

et al. 2015

Bone

View full text Add to dashboard Cite

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2010

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 23 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Antidiabetic Agents; 21 Contrast Agents; 22 Bone Conservation Agents; 23 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Differences in utilisation of gastroprotective drugs between 2001 and 2005 in Australia and Nova Scotia, Canada

Tett

Sketris

Cooke

et al. 2013

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

show abstract

Prescribing of anti‐osteoporotic therapies following the use of proton pump inhibitors in general practice

Abstract: The results of the study indicate the association between the prescribing of bisphosphonates following the use of proton pump inhibitors may be clinically relevant.

Cited by 12 publications

References 44 publications

The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study

The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study

Current awareness: Pharmacoepidemiology and drug safety

Differences in utilisation of gastroprotective drugs between 2001 and 2005 in Australia and Nova Scotia, Canada

Contact Info

Product

Resources

About